ClinicalTrials.gg
CompletedNCT01646255Updated Apr 4, 2018Results posted

Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients

A Phase 3 interventional study of Rotigotine and Placebo Patch in Idiopathic Parkinson's Disease, sponsored by UCB Pharma. Completed at 24 sites in China. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2018-04-04.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
346
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
8th of 42
346 · median 123
Started
2012
with 7 others
Phase 3
20 of 44
none open now
Registered
29th of 44
by date
Lead sponsor
22 of 44
UCB Pharma

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 8th largest by enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2012, is one of 20 in phase 3, and was the 29th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

The primary objective of this study was to demonstrate that Rotigotine transdermal patch is efficacious in Chinese subjects with advanced-stage Idiopathic Parkinson's Disease as an adjuvant therapy.

Read the detailed description

The study included a maximum 4-week Screening Period, a maximum 7-week Titration Period for advanced-stage Parkinson's disease, 12-week Maintenance Period, a maximum 12-day De-escalation Period for advanced-stage Parkinson's Disease and 30-day Safety Follow-Up Period. The maximum study duration for an individual subject with advanced-stage Parkinson's disease was 27 weeks.

03

Conditions studied

  • Idiopathic Parkinson's Disease

Browse trials for

Keywords

  • Rotigotine
  • Neupro phase 3
  • Advanced-stage
  • Idiopathic Parkinson's Disease
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria:

  • An Independent Ethics Committee (IEC)-approved written is signed and dated by the subject or by the legal representative
  • Subject/legal representative is considered reliable and capable of adhering to the protocol (eg, able to understand and complete diaries), visit schedule, and medication application according to the judgment of the investigator
  • Subject has Idiopathic Parkinson's Disease of more than 3 years' duration, defined by the cardinal sign, Bradykinesia, plus the presence of at least 1 of the following: resting tremor, rigidity, or impairment of postural reflexes, and without any other known or suspected cause of Parkinsonism
  • The investigator must observe the subject in both the 'on' and 'off' state and determine that the subject is Hoehn \& Yahr stage 2 through 4 in both the 'on' and 'off' state
  • Subject is male or female and aged ≥30 years at Screening (Visit 1)
  • Subject has a (MMSE) score of ≥25 at Screening (Visit 1)
  • Subject must be on a stable dose of L-dopa (either short-acting or sustained release [in combination with Benserazide or Carbidopa]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline (Visit 2)
  • Subject is not adequately controlled on a L-dopa dose (in combination with Benserazide or Carbidopa) which was judged by the treating physician to be optimal
  • Subject must be willing and able to accurately complete a subject diary on designated days (with assistance from caregivers, if required), recording periods when they are 'on without troublesome Dyskinesia', 'on with troublesome Dyskinesia', 'off', and sleeping
  • As part of the Screening (pretreatment) assessments, the subject must complete a diary over a period of 6 days, with 4 of the 6 diaries being 'valid' as determined by the investigator (see Section 9.1.1)
  • It must be clear to the investigator that the subject is able to differentiate between the 'on' and 'off' state and the 'valid' diaries confirm that the subject has an average of ≥2.5 h/day spent in the 'off' state
  • If the subject is receiving an Anticholinergic agent (eg, Benztropine, Trihexyphenidyl, Parsitan, Procyclidine, Biperiden), a monoamine oxidase (MAO)-B inhibitor (eg, Selegiline), and/or an N-methyl-d-aspartate (NMDA) antagonist (eg, Amantadine), he/she must have been on a stable dose for at least 28 days prior to Baseline (Visit 2) and be maintained on that dose for the duration of the study
  • Subject must be on a stable dose of all anti-Parkinsonian medications for at least 20 days prior to completing the 6 Baseline diaries

Exclusion Criteria:

  • Subject has previously participated in this study or subject has previously received the study medication under investigation in this study
  • Subject is participating in another study of an drug or has done so within 28 days prior to the Baseline Visit (Visit 2)
  • Subject has a history of significant skin to adhesive or other transdermal preparations, or recent unresolved contact dermatitis
  • Subject has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening (Visit 1)
  • Subject has atypical Parkinson's syndrome(s) due to drugs (eg, Metoclopramide, Flunarizine), Metabolic Neurogenetic Disorders (eg, Wilson's Disease), Encephalitis, Cerebrovascular Disease, or Degenerative Disease (eg, Progressive Supranuclear Palsy)
  • Subject has a history of Pallidotomy, Thalamotomy, deep brain stimulation, or fetal tissue transplant
  • Subject has dementia, active psychosis or hallucinations, or severe depression
  • Subject is receiving therapy with a Dopamine agonist either concurrently or has done so within 28 days prior to the Baseline Visit (Visit 2)
  • Subject is receiving therapy with 1 of the following drugs either concurrently or within 28 days prior to Baseline (Visit 2): Alpha-methyl dopa, Metoclopramide, Reserpine, Neuroleptics (except specific atypical neuroleptics: Olanzapine, Ziprasidone, Aripiprazole, Clozapine, quetiapine), MAO-A inhibitors, Methylphenidate, or Amphetamine
  • Subject is currently receiving central nervous system (CNS) active therapy (eg, sedatives, hypnotics, antidepressants, anxiolytics), unless the dose has been stable for at least 28 days prior to Baseline (Visit 2) and is likely to remain stable for the duration of the study
  • Subject has a current diagnosis of Epilepsy, has a history of seizures as an adult, has a history of stroke, or has had a within 1 year prior to Screening (Visit 1)
  • Subject has hepatic dysfunction (as defined as a total >2.0 mg/dL, or (ALT) and/or Aspartate Aminotransferase (AST) >2 times the upper limit of the reference range)
  • Subject has clinically relevant renal dysfunction (serum creatinine >2.0 mg/dL [>178 μmol/L])
  • Subject has clinically relevant cardiac dysfunction (any cardiac disorder which in the opinion of the investigator would put the subject at risk of clinically relevant arrhythmia) and/or myocardial infarction within the last 12 months
  • Subject has a corrected for heart rate according to Bazett's formula (QTcB) of ≥500 ms at Screening (Visit 1)
  • Subject has a history of only symptomatic (not asymptomatic) orthostatic hypotension, with a decrease of systolic blood pressure (SBP) from supine to standing position of ≥2 0 mmHg or of ≥10 mmHg in DBP after 1 or 3 minutes within 28 days prior to Baseline (Visit 2), or SBP \<105 mmHg at study entry 17. Subject has evidence of an impulse control disorder (ICD) at Screening (Visit 1)
  • Subject has a history of known intolerance/hypersensitivity to the following Antiemetics: Domperidone, Trimethobenzamide, Ondansetron, Tropisetron, Granisetron, and Glycopyrrolate
  • Subject has a history of chronic alcohol or drug abuse within the last 5 years
  • Subject is pregnant or nursing, or is of but (i) not surgically sterile or (ii) not using adequate methods (including at least a double barrier method) or (iii) not sexually abstinent or (iv) not at least 2 years
  • Subject has any other clinically relevant medical condition, psychiatric condition, or laboratory abnormality which would, in the judgment of the investigator, interfere with the subject's ability to participate in the study

Exclusion Criteria:

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
346 participants (actual)

Study arms

  • Experimental
    Rotigotine

    Rotigotine, daily doses, treatment group

    Drug: Rotigotine · Drug: L-dopa

  • Placebo comparator
    Placebo

    Placebo, daily doses, placebo group

    Drug: Placebo Patch · Drug: L-dopa

Interventions

  • Transdermal Patch Content: 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2) For advanced-stage Parkinson's Disease, subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 12 week maintenance period

  • DrugPlacebo Patch

    Transdermal Patch Size: 20 cm\^2, 30 cm\^2, 40 cm\^2 Subjects randomized to placebo received matching placebo patches

  • DrugL-dopa

    Subject must be on a stable dose of L-dopa (either short-acting or sustained release \[in combination with benserazide or carbidopa\]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.

    Also known as: Levodopa

06

What researchers measure

Primary outcomes

  1. Absolute Change in Absolute Time Spent 'Off' From Baseline to the End of Double-blind Maintenance Period

    A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication. A negative mean indicates a reduction of the time off during the conduct of the study

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)

Secondary outcomes

  1. Percentage of Responders From Baseline to the End of the Doubleblind Maintenance Period

    A Responder is defined as a subject with an ≥ 30 % decrease in absolute time spent 'off'

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)

  2. Percent Change in Absolute Time Spent "Off" From Baseline to the End of Double-blind Maintenance Period

    A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication. Absolute time "off" is defined as the mean number of hours marked "off" during a 24-hour period from all valid daily diary cards.

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)

  3. Percent Change in Relative Time Spent "Off" From Baseline to the End of Double-blind Maintenance Period

    A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication. Relative time spent "off" will be calculated in two stages. Each valid daily diary will have an associated relative time "off" calculated as relative time "off" for day = 100\*\[total absolute time "off" for day/ absolute time awake for day\]. Relative time spent "off" is then calculated by averaging the daily relative time "off" for the valid days of that visit.

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)

  4. Change in Absolute Time Spent "on" From Baseline to the End of Double-blind Maintenance Period

    A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'. Absolute time "on" is defined as the mean number of hours marked "on" during a 24-hour period from all valid daily diary cards.

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)

  5. Change in Relative Time Spent "on" From Baseline to the End of Double-blind Maintenance Period

    A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was "off" when taking his/her L-dopa, he/she recorded the exact time their status changed to "on". Relative time spent "on" will be calculated in two stages. Each valid daily diary will have an associated relative time "on" calculated as relative time "on" for day = 100\*\[total absolute time "on" for day/ absolute time awake for day\]. Relative time spent "on" is then calculated by averaging the daily relative time "on" for the valid days of that visit.

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)

  6. Percent Change in Absolute Time Spent "on" From Baseline to the End of Double-blind Maintenance Period

    A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'. Note for percent change calculations: when absolute time at Baseline was 0 hours, the absolute Baseline value was assumed to be 1 minute for calculation purposes.

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)

  7. Percent Change in Relative Time Spent "on" From Baseline to the End of Double-blind Maintenance Period

    A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was "off" when taking his/her L-dopa, he/she recorded the exact time their status changed to "on". Note for percent change calculations: when relative time at Baseline was 0%, the relative Baseline value was assumed to be 0.1 for calculation purposes. Relative time spent "on" will be calculated in two stages. Each valid daily diary will have an associated relative time "on" calculated as relative time "on" for day = 100\*\[total absolute time "on" for day/ absolute time awake for day\]. Relative time spent "on" is then calculated by averaging the daily relative time "on" for the valid days of that visit.

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)

  8. Change in the Number of "Off" Periods From Baseline to the End of Double-blind Maintenance Period

    A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication.

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)

  9. Change in Status of the Subject (on) After Wake-up With Troublesome Dyskinesia From Baseline to the End of Double-blind Maintenance Period

    A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'. The percentage of days from Baseline to the end of the double-blind Maintenance Period in which the subject woke in the "on with troublesome dyskinesia" state is presented below.

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)

  10. Change in Status of the Subject (on) After Wake-up Without Troublesome Dyskinesia From Baseline to the End of Double-blind Maintenance Period

    A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'. The percentage of days from Baseline to the end of the double-blind Maintenance Period in which the subject woke in the "on without troublesome dyskinesia" state is presented below.

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)

  11. Change in Status of the Subject (Off) After Wake-up From Baseline to the End of Double-blind Maintenance Period

    A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication. The percentage of days from Baseline to the end of the double-blind Maintenance Period in which the subject woke in the "off" state is presented below.

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)

  12. Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "on" Periods From Baseline to the End of Double-blind Maintenance Period

    The UPDRS Part III (motor subscale) assessment consists of 27 questions, measured on a 5-Point scale (0 to 4). The sum score is calculated as sum of these 27 individual questions. This score ranges from 0 to 108, higher scores denote greater disability. A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'.

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 12)

07

Results

Posted Jan 22, 2016

Participant flow

This multicenter, randomized, double-blind, parallel-group, placebo-controlled study started recruiting in August 2012.

Participant flow — Overall Study
MilestonePlaceboRotigotine
Started172174
Completed151160
Not completed2114
Withdrew: Adverse event78
Withdrew: Lack of efficacy20
Withdrew: Withdrawal by subject106
Withdrew: Compliance is not well10
Withdrew: Inclusion criteria deviation10

Outcome measures

PrimaryAbsolute Change in Absolute Time Spent 'Off' From Baseline to the End of Double-blind Maintenance Period

A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication. A negative mean indicates a reduction of the time off during the conduct of the study

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Reported as:
Mean · hours
Absolute Change in Absolute Time Spent 'Off' From Baseline to the End of Double-blind Maintenance Period
hoursFull Analysis Set (Placebo Treated Subjects)Full Analysis Set (Rotigotine Treated Subjects)
Absolute Change in Absolute Time Spent 'Off' From Baseline to the End of Double-blind Maintenance Period-1.13 ± 3.20-2.36 ± 2.83
Statistical analysis
  • Full Analysis Set (Placebo Treated Subjects) vs Full Analysis Set (Rotigotine Treated Subjects) · ANCOVA · p = =0.0002 (Primary efficacy analyses was made with confirmatory 2-sided test with significance level 0.05.) · Least square mean: -1.20 · 95% CI -1.83 to -0.57
SecondaryPercentage of Responders From Baseline to the End of the Doubleblind Maintenance Period

A Responder is defined as a subject with an ≥ 30 % decrease in absolute time spent 'off'

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Reported as:
Number · percentage of participants
Percentage of Responders From Baseline to the End of the Doubleblind Maintenance Period
percentage of participantsFull Analysis Set (Placebo Treated Subjects)Full Analysis Set (Rotigotine Treated Subjects)
Percentage of Responders From Baseline to the End of the Doubleblind Maintenance Period36.948.8
SecondaryPercent Change in Absolute Time Spent "Off" From Baseline to the End of Double-blind Maintenance Period

A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication. Absolute time "off" is defined as the mean number of hours marked "off" during a 24-hour period from all valid daily diary cards.

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Reported as:
Mean · percent change
Percent Change in Absolute Time Spent "Off" From Baseline to the End of Double-blind Maintenance Period
percent changeFull Analysis Set (Placebo Treated Subjects)Full Analysis Set (Rotigotine Treated Subjects)
Percent Change in Absolute Time Spent "Off" From Baseline to the End of Double-blind Maintenance Period-15.0 ± 56.56-36.03 ± 43.03
SecondaryPercent Change in Relative Time Spent "Off" From Baseline to the End of Double-blind Maintenance Period

A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication. Relative time spent "off" will be calculated in two stages. Each valid daily diary will have an associated relative time "off" calculated as relative time "off" for day = 100\*\[total absolute time "off" for day/ absolute time awake for day\]. Relative time spent "off" is then calculated by averaging the daily relative time "off" for the valid days of that visit.

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Reported as:
Mean · percent change
Percent Change in Relative Time Spent "Off" From Baseline to the End of Double-blind Maintenance Period
percent changeFull Analysis Set (Placebo Treated Subjects)Full Analysis Set (Rotigotine Treated Subjects)
Percent Change in Relative Time Spent "Off" From Baseline to the End of Double-blind Maintenance Period-14.86 ± 53.26-34.97 ± 43.87
SecondaryChange in Absolute Time Spent "on" From Baseline to the End of Double-blind Maintenance Period

A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'. Absolute time "on" is defined as the mean number of hours marked "on" during a 24-hour period from all valid daily diary cards.

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Reported as:
Mean · hours
Change in Absolute Time Spent "on" From Baseline to the End of Double-blind Maintenance Period
hoursFull Analysis Set (Placebo Treated Subjects)Full Analysis Set (Rotigotine Treated Subjects)
Change in Absolute Time Spent "on" From Baseline to the End of Double-blind Maintenance Period0.94 ± 3.082.05 ± 2.98
SecondaryChange in Relative Time Spent "on" From Baseline to the End of Double-blind Maintenance Period

A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was "off" when taking his/her L-dopa, he/she recorded the exact time their status changed to "on". Relative time spent "on" will be calculated in two stages. Each valid daily diary will have an associated relative time "on" calculated as relative time "on" for day = 100\*\[total absolute time "on" for day/ absolute time awake for day\]. Relative time spent "on" is then calculated by averaging the daily relative time "on" for the valid days of that visit.

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Reported as:
Mean · hours
Change in Relative Time Spent "on" From Baseline to the End of Double-blind Maintenance Period
hoursFull Analysis Set (Placebo Treated Subjects)Full Analysis Set (Rotigotine Treated Subjects)
Change in Relative Time Spent "on" From Baseline to the End of Double-blind Maintenance Period6.78 ± 19.6114.49 ± 18.70
SecondaryPercent Change in Absolute Time Spent "on" From Baseline to the End of Double-blind Maintenance Period

A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'. Note for percent change calculations: when absolute time at Baseline was 0 hours, the absolute Baseline value was assumed to be 1 minute for calculation purposes.

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Reported as:
Mean · percent change
Percent Change in Absolute Time Spent "on" From Baseline to the End of Double-blind Maintenance Period
percent changeFull Analysis Set (Placebo Treated Subjects)Full Analysis Set (Rotigotine Treated Subjects)
Percent Change in Absolute Time Spent "on" From Baseline to the End of Double-blind Maintenance Period13.53 ± 42.74368.55 ± 4446.55
SecondaryPercent Change in Relative Time Spent "on" From Baseline to the End of Double-blind Maintenance Period

A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was "off" when taking his/her L-dopa, he/she recorded the exact time their status changed to "on". Note for percent change calculations: when relative time at Baseline was 0%, the relative Baseline value was assumed to be 0.1 for calculation purposes. Relative time spent "on" will be calculated in two stages. Each valid daily diary will have an associated relative time "on" calculated as relative time "on" for day = 100\*\[total absolute time "on" for day/ absolute time awake for day\]. Relative time spent "on" is then calculated by averaging the daily relative time "on" for the valid days of that visit.

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Reported as:
Mean · percent change
Percent Change in Relative Time Spent "on" From Baseline to the End of Double-blind Maintenance Period
percent changeFull Analysis Set (Placebo Treated Subjects)Full Analysis Set (Rotigotine Treated Subjects)
Percent Change in Relative Time Spent "on" From Baseline to the End of Double-blind Maintenance Period14.99 ± 42.60616.80 ± 7667.58
SecondaryChange in the Number of "Off" Periods From Baseline to the End of Double-blind Maintenance Period

A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication.

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Reported as:
Mean · Number of 'off' Periods
Change in the Number of "Off" Periods From Baseline to the End of Double-blind Maintenance Period
Number of 'off' PeriodsFull Analysis Set (Placebo Treated Subjects)Full Analysis Set (Rotigotine Treated Subjects)
Change in the Number of "Off" Periods From Baseline to the End of Double-blind Maintenance Period-0.61 ± 1.59-0.89 ± 1.32
SecondaryChange in Status of the Subject (on) After Wake-up With Troublesome Dyskinesia From Baseline to the End of Double-blind Maintenance Period

A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'. The percentage of days from Baseline to the end of the double-blind Maintenance Period in which the subject woke in the "on with troublesome dyskinesia" state is presented below.

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Reported as:
Mean · percentage of days
Change in Status of the Subject (on) After Wake-up With Troublesome Dyskinesia From Baseline to the End of Double-blind Maintenance Period
percentage of daysFull Analysis Set (Placebo Treated Subjects)Full Analysis Set (Rotigotine Treated Subjects)
Change in Status of the Subject (on) After Wake-up With Troublesome Dyskinesia From Baseline to the End of Double-blind Maintenance Period2.42 ± 21.701.24 ± 16.90
SecondaryChange in Status of the Subject (on) After Wake-up Without Troublesome Dyskinesia From Baseline to the End of Double-blind Maintenance Period

A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'. The percentage of days from Baseline to the end of the double-blind Maintenance Period in which the subject woke in the "on without troublesome dyskinesia" state is presented below.

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Reported as:
Mean · percentage of days
Change in Status of the Subject (on) After Wake-up Without Troublesome Dyskinesia From Baseline to the End of Double-blind Maintenance Period
percentage of daysFull Analysis Set (Placebo Treated Subjects)Full Analysis Set (Rotigotine Treated Subjects)
Change in Status of the Subject (on) After Wake-up Without Troublesome Dyskinesia From Baseline to the End of Double-blind Maintenance Period7.92 ± 43.2922.55 ± 45.41
SecondaryChange in Status of the Subject (Off) After Wake-up From Baseline to the End of Double-blind Maintenance Period

A subject has been considered "off" when he/she began to lose the optimum effects of anti-Parkinson's medication. The percentage of days from Baseline to the end of the double-blind Maintenance Period in which the subject woke in the "off" state is presented below.

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Reported as:
Mean · percentage of days
Change in Status of the Subject (Off) After Wake-up From Baseline to the End of Double-blind Maintenance Period
percentage of daysFull Analysis Set (Placebo Treated Subjects)Full Analysis Set (Rotigotine Treated Subjects)
Change in Status of the Subject (Off) After Wake-up From Baseline to the End of Double-blind Maintenance Period-10.34 ± 47.81-21.14 ± 48.49
SecondaryChange in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "on" Periods From Baseline to the End of Double-blind Maintenance Period

The UPDRS Part III (motor subscale) assessment consists of 27 questions, measured on a 5-Point scale (0 to 4). The sum score is calculated as sum of these 27 individual questions. This score ranges from 0 to 108, higher scores denote greater disability. A subject has been considered "on" when he/she felt the effects of L-dopa. The subject recorded the exact time of L-dopa intake and his/her status at the time of the L-dopa dose. In instances when the subject was 'off' when taking his/her L-dopa, he/she recorded the exact time their status changed to 'on'.

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 12)
Reported as:
Mean · units on a scale
Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "on" Periods From Baseline to the End of Double-blind Maintenance Period
units on a scaleFull Analysis Set (Placebo Treated Subjects)Full Analysis Set (Rotigotine Treated Subjects)
Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "on" Periods From Baseline to the End of Double-blind Maintenance Period-3.6 ± 9.8-10.4 ± 10.4

Adverse events

Collected over Treatment-emergent Adverse Events (TEAE) were collected during the study, which began in August 2012 and concluded in October 2014.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—6/172 (3.5%)24/172 (14%)
Rotigotine—6/174 (3.4%)54/174 (31%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlaceboRotigotine
SyncopeNervous system disorders0/1722/174
Mitral valve prolapseCardiac disorders1/1720/174
Atrial fibrillationCardiac disorders1/1720/174
Intestinal obstructionGastrointestinal disorders1/1720/174
Parkinson's diseaseNervous system disorders1/1720/174
Urinary retentionRenal and urinary disorders1/1720/174
VasculitisVascular disorders1/1720/174
Inguinal herniaGastrointestinal disorders0/1721/174
Gastrointestinal haemorrhageGastrointestinal disorders0/1721/174
Skin infectionInfections and infestations0/1721/174
Most frequent other events
Most frequent other events
EventPlaceboRotigotine
DizzinessNervous system disorders7/17219/174
NauseaGastrointestinal disorders2/17216/174
PruritusSkin and subcutaneous tissue disorders10/17214/174
DyskinesiaNervous system disorders7/17211/174

Baseline characteristics

Baseline Characteristics refers to to the Safety Set (SS), consisting of all randomized subjects who received at least 1 dose of study medication.

Age, Categorical
Age, Categorical(Participants)PlaceboRotigotineTotal Title
<=18 years000
Between 18 and 65 years96111207
>=65 years7663139
Age, Continuous
Age, Continuous(years)PlaceboRotigotineTotal Title
mean (standard deviation)62.8 ± 9.161.7 ± 8.862.2 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRotigotineTotal Title
Female6281143
Male11093203
Weight
Weight(kg)PlaceboRotigotineTotal Title
Mean61.83 ± 10.1860.38 ± 10.1561.10 ± 10.18
08

Study locations

24 sites
  • Sp1037 001
    Beijing, China
  • Sp1037 002
    Beijing, China
  • Sp1037 019
    Beijing, China
  • Sp1037 025
    Beijing, China
  • Sp1037 017
    Changchun, China
  • Sp1037 007
    Chengdu, China
  • Sp1037 027
    Chengdu, China
  • Sp1037 021
    Fuzhou, China
  • Sp1037 010
    Guangzhou, China
  • Sp1037 011
    Guangzhou, China
  • Sp1037 014
    Guangzhou, China
  • Sp1037 015
    Guangzhou, China
  • Sp1037 005
    Hangzhou, China
  • Sp1037 013
    Hangzhou, China
  • Sp1037 018
    Hangzhou, China
  • Sp1037 023
    Jinan, China
  • Sp1037 003
    Shanghai, China
  • Sp1037 004
    Shanghai, China
  • Sp1037 009
    Shanghai, China
  • Sp1037 008
    Suzhou, China
  • Sp1037 016
    Tianjin, China
  • Sp1037 006
    Wuhan, China
  • Sp1037 022
    Wuhan, China
  • Sp1037 024
    Wuhan, China
09

References and documents

Publications

  • Zhang ZX, Liu CF, Tao EX, Shao M, Liu YM, Wang J, Asgharnejad M, Xue HB, Surmann E, Bauer L. Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study. Parkinsonism Relat Disord. 2017 Nov;44:6-12. doi: 10.1016/j.parkreldis.2017.08.015. Epub 2017 Aug 10. PubMed 28827011 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2012
First posted
Jul 20, 2012
Start
Jul 2012
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results first posted
Jan 22, 2016
Last update
Apr 4, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01646255
Lead sponsor
UCB Pharma
Collaborators
UCB Trading (Shanghai) Co. Ltd.
Responsible party
Sponsor
First posted
Jul 20, 2012
Start date
Jul 2012
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Jan 22, 2016
Last update
Apr 4, 2018

Study contacts

UCB Clinical Trial Call Center
study director · 1 877 822 9493

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion